Invasive Candidiasis clinical trials

Explore recruiting invasive candidiasis clinical trials.

Recruiting invasive candidiasis studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Invasive Candidiasis trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Rezafungin plasma concentrations in patients with or without extracorporal treatments (ECMO ± RRT)

Austria

Phase III and phase IV (Integrated) EU CTIS Study details

A Phase 3, Multicenter, Prospective, Randomized, Double-blind Study of Two Treatment Regimens for Candidemia and/or Invasive Candidiasis: Intravenous Echinocandin followed by Oral Ibrexafungerp versus Intravenous Echinocandin followed by Oral Fluconazole (MARIO)

Germany, Spain, Bulgaria, Belgium, France, Greece +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A multicenter, randomized, double-blind, placebo-controlled, adaptive, non-inferiority trial to investigate shortening treatment duration in uncomplicated candidemia: the CanTEN trial

Germany

Therapeutic use (Phase IV) EU CTIS Study details

An interventional efficacy and safety Phase 3 double-blind 2-arm study to investigate IV followed by oral fosmanogepix compared with IV caspofungin followed by oral fluconazole in adult participants with candidemia and/or invasive candidiasis.

Belgium, Italy, Germany, France, Bulgaria, Austria +2 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3, Multicenter, Randomized, Double-Blind Study of the Efficacy and Safety of Rezafungin for Injection Versus the Standard Antimicrobial Regimen to Prevent Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation (The ReSPECT Study)

France, Italy, Germany, Belgium, Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

Dexamethasone for treating severe hospital-acquired pneumonia in critically ill patients with a proinflammatory phenotype, an international phase III, double-blind, placebo-controlled, randomized trial - the HAP-DEX study

France, Belgium, Greece, Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

Invasive Candidiasis trials by city

Invasive Candidiasis in Toronto Invasive Candidiasis in Vancouver Invasive Candidiasis in Montreal Invasive Candidiasis in Calgary Invasive Candidiasis in Edmonton Invasive Candidiasis in Ottawa Invasive Candidiasis in Winnipeg Invasive Candidiasis in Quebec City Invasive Candidiasis in Hamilton Invasive Candidiasis in Kitchener Invasive Candidiasis in London Invasive Candidiasis in Halifax Invasive Candidiasis in New York Invasive Candidiasis in Los Angeles Invasive Candidiasis in Chicago Invasive Candidiasis in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease